GW Pharmaceuticals PLC Notice of Results (1622D)

TIDMGWP

RNS Number : 1622D

GW Pharmaceuticals PLC

27 January 2015

GW Pharmaceuticals to Report Q1, 2015 Financial Results and Host Conference Call on 4 February, 2015

London, UK, 27 January 2015: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will report on 4 February, 2015 its first quarter financial results for the period ending 31 December, 2014. GW will also host a conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT.

Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R) , which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. GW is also advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R) , which is in Phase 2/3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

 
 GW Pharmaceuticals plc                        (Today) [phone] 
 Justin Gover, Chief Executive Officer         (Thereafter) + 44 1980 557000 
 Stephen Schultz, VP Investor Relations 
  (U.S.)                                       917 280 2424 / 401 500 6570 
 
 FTI Consulting (Media Enquiries) 
 Ben Atwell / Simon Conway / John Dineen 
  (UK)                                         + 44 20 3727 1000 
 Robert Stanislaro (U.S.)                      212 850 5657 
 
 Trout Group, LLC (U.S. investor relations) 
 Todd James / Chad Rubin                       646 378 2900 
 Peel Hunt LLP (UK NOMAD)                      [phone] 
 James Steel / Clare Terlouw 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOREQLFLEFFZBBF